PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/41, 31/415, A61P 9/10 — A1

(11) International Publication Number: WO 00/44378

(43) International Publication Date: 3 August 2000 (03.08.00)

(21) International Application Number: PCT/EP00/00525

(22) International Filing Date: 24 January 2000 (24.01.00)

(30) Priority Data:

99810061.4	26 January 1999 (26.01.99)	EP
09/468,664	21 December 1999 (21.12.99)	US

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(71) Applicant *(for all designated States except AT US)*: NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH–4058 Basel (CH).

(71) Applicant *(for AT only)*: NOVARTIS–ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A–1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: MANN, Jessica, M. [DE/CH]; Spalenberg 14, CH–4051 Basel (CH). ODDOU, Pascale [FR/CH]; Spalenvorstadt 35, CH–4051 Basel (CH). NEUHART, Eric, Michel [FR/FR]; 46, rue des Trois Rois, F–68100 Mulhouse (FR).

(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH–4002 Basel (CH).

(54) Title: USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS FOR TREATING ACUTE MYOCARDIAL INFARCTION

(57) Abstract

The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.